Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
Shinsuke Amano, executive director of the Japan Federation of Cancer Patient Groups, at a Diet session on April 8 urged lawmakers to revise the advertising regulations related to clinical trial information stipulated in the Pharmaceuticals and Medical Devices (PMD) Act.…
To read the full story
Related Article
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
March 27, 2026
- Regulatory Reform Panel Calls for Review of Clinical Trial Ad Rules
May 30, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
- Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
REGULATORY
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
- Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout
June 22, 2026
- LDP Group Calls for Pediatric Cancer Drug Development Platform
June 22, 2026
- LDP Group Seeks Better Access to Advanced Eczema Care
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…